NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Myers ER, Bastian LA, Havrilesky LJ, et al. Management of Adnexal Mass. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb. (Evidence Reports/Technology Assessments, No. 130.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Management of Adnexal Mass

Management of Adnexal Mass.

Show details

References Cited in the Evidence Report

1.
Jemal A, Murray T, Samuels A. et al. Cancer statistics, 2003. Ca: Cancer J Clin. 2003;53(1):5–26. [PubMed: 12568441]
2.
Anonymous. SEER Stat Databases: Incidence - SEER Regs Public - Use, Nov 2004 Sub for Expanded Races (1992-2002) and Incidence - SEER 13 Regs excluding AK Public - Use Nov 2004 Sub for Hispanics (1992-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on November 2004 submission. Available at: www​.seer.cancer.gov. Accessed: May 25, 2005.
3.
Russell P, Robboy S, Anderson M. Ovarian tumors: classification and clinical perspective. In: Robboy SJ, Anderson MC, and Russell P, editors. Pathology of the female reproductive tract. London: Churchill Livingstone; 2002. p. 527–38.
4.
Eheman C, Bobo J, Lawson H, et al. Identifying public health opportunities to reduce the burden of ovarian cancer: workshop summary. Atlanta, Ga. Centers for Disease Control and Prevention, 2001. Available at: www​.cdc.gov/cancer/ovarian/workshop​.htm#conclusion. Accessed: May 25, 2005.
5.
Eheman C, Brustrom J, Lawson H. The use of ultrasound in diagnosing ovarian cancer: can we improve on current practice? workshop summary. Atlanta, GA: Centers for Disease Control and Prevention, 2002. Accessed: http://www.cdc.gov/cancer/ovarian/workshop.htm. Accessed: May 25, 2005.
6.
Russell P, Robboy S, Anderson M. The ovary: normal appearances and non-neoplastic conditions. In: Robboy SJ, Anderson MC, and Russell P, editors. Pathology of the female reproductive tract. London: Churchill Livingstone; 2002. p. 475–526.
7.
Barber H, Graber E. The PMPO syndrome (postmenopausal palpable ovary syndrome) Obstet and Gynecol. 1971;38(6):921–3. [PubMed: 5125444]
8.
Munstedt K, von Georgi R, Misselwitz B. et al. Centralizing surgery for gynecologic oncology—a strategy assuring better quality treatment? [see comment] Gynecol Oncol. 2003;89(1):4–8. [PubMed: 12694647]
9.
Junor E, Hole D, McNulty L. et al. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol. 1999;106(11):1130–6. [PubMed: 10549956]
10.
Tingulstad S, Skeldestad FE, Hagen B. The effect of centralization of primary surgery on survival in ovarian cancer patients. Obstet Gynecol. 2003;102(3):499–505. [PubMed: 12962932]
11.
American College of Obstetricians and Gynecologists. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol. 2002;100(6):1413–6. [PubMed: 12468197]
12.
American Academy of Family Physicians. Summary of recommendations for periodic health examinations. Leawood (KS):American Academy of Family Physicians. 2004.
13.
Geomini P, Bremer G, Kruitwagen R. et al. Diagnostic accuracy of frozen section diagnosis of the adnexal mass: a metaanalysis. Gynecol Oncol. 2005;96(1):1–9. [PubMed: 15589572]
14.
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin 45. Cervical cytology screening. August 2003. 2003.
15.
Whiting P, Rutjes A, Reitsma JB. et al. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern. Med. 2004;140(3):189–202. [PubMed: 14757617]
16.
Gohagan J, Prorok P, Hayes R. et al. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization and status. Control Clin Trials. 2000;21(6Suppl):251S–72S. [PubMed: 11189683]
17.
Prorok P, Andriole G, Bresalier R. et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21(6 Suppl):273S–309S. [PubMed: 11189684]
18.
Jacobs I. European randomized trial of ovarian cancer screening (protocol). London: Wolfson Institute of Preventive Medicine, Department of Environmental and Preventive Medicine. 1995.
19.
Goff B, Mandel L, Melancon C. et al. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. [see comment] JAMA. 2004;291(22):2705–12. [PubMed: 15187051]
20.
Thompson ISI ReseachSoft. ProCite [computer program]. Berkeley, CA: Thompson ISI ResearchSoft.
21.
Nanda K, McCrory D, Myers E. et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med. 2000;132(10):810–9. [PubMed: 10819705]
22.
Lau J. Meta-Stat 0.6. Shareware program for performing meta-analyses of diagnostic tests. Available at: www​.medepi.net/meta/software​/MetaTest/Mtreadme.txt. Accessed August 26, 2005.
23.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. [PubMed: 3802833]
24.
Moses LE, Shapiro D. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med. 1993;12:1293–316. [PubMed: 8210827]
25.
Agency for Healthcare Research and Quality. Overview of the HCUP Nationwide Inpatient Sample. Rockville, MD. 2003.
26.
Myers E, Steege J. Risk adjustment for complications of hysterectomy:utility of routinely collected administrative data. Am J Obstet Gynecol. 1999;181:567–75. [PubMed: 10486465]
27.
Ries L, Eisner M, Kosary C, et al. SEER Cancer Statistics Review, 1973-1999. National Cancer Institute: Bethesda, MD. 2002.
28.
Anderson R, DeTurk P. National vital statistics reports: United States life tables, 1999. National Center for Health Statistics: Hyattsville, MD. 2002. [PubMed: 25077730]
29.
Jones H. Ovarian Cancer: The Clinical Problem in Early Detection of Ovarian Carcinoma with Transvaginal Sonography: Potentials and Limitations, H.W. Jones, editor. Raven Press, Ltd.: New York. 1993;3–9.
30.
TreeAge Software. DATA 4.0 [computer program]. Williamstown, MA: TreeAge Software, Inc.
31.
Chalas E, Welshinger M, Engellener W. et al. The clinical significance of thrombocytosis in women presenting with a pelvic mass. Am J Obstet Gynecol. 1992;166(3):974–7. [PubMed: 1550175]
32.
Childers JM, Nasseri A, Surwit EA. Laparoscopic management of suspicious adnexal masses. Am J Obstet Gynecol. 1996;175(6):1451–7. discussion 1457–9. [PubMed: 8987924]
33.
Cohen LS, Escobar PF, Scharm C. et al. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol. 2001;82(1):40–8. [PubMed: 11426960]
34.
DePriest PD, Gallion HH, Pavlik EJ. et al. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol. 1997;65(3):408–14. [PubMed: 9190966]
35.
DePriest PD, Shenson D, Fried A. et al. A morphology index based on sonographic findings in ovarian cancer. Gynecol Oncol. 1993;51(1):7–11. [PubMed: 8244178]
36.
DePriest PD, van Nagell JR Jr, Gallion HH. et al. Ovarian cancer screening in asymptomatic postmenopausal women. Gynecol Oncol. 1993;51(2):205–9. [PubMed: 8276295]
37.
Dottino PR, Levine DA, Ripley DL. et al. Laparoscopic management of adnexal masses in premenopausal and postmenopausal women. Obstet Gynecol. 1999;93(2):223–8. [PubMed: 9932560]
38.
Fleischer AC, Cullinan JA, Jones HW 3rd. et al. Correlation of histomorphology of ovarian masses with color Doppler sonography. Ultrasound Med Biol. 1996;22(5):555–9. [PubMed: 8865552]
39.
Lin JY, Angel C, DuBeshter B. et al. Diagnoses after laparotomy for a mass in the pelvic area in women. Surg Gynecol Obstet. 1993;176(4):333–8. [PubMed: 8460408]
40.
Modesitt SC, Pavlik EJ, Ueland FR. et al. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol. 2003;102(3):594–9. [PubMed: 12962948]
41.
Parker WH, Levine RL, Howard FM. et al. A multicenter study of laparoscopic management of selected cystic adnexal masses in postmenopausal women. J Am Coll Surg. 1994;179(6):733–7. [PubMed: 7952486]
42.
Roman LD, Muderspach LI, Stein SM. et al. Pelvic examination, tumor marker level, and gray-scale and Doppler sonography in the prediction of pelvic cancer. Obstet Gynecol. 1997;89(4):493–500. [PubMed: 9083301]
43.
Schneider VL, Schneider A, Reed KL. et al. Comparison of Doppler with two-dimensional sonography and CA 125 for prediction of malignancy of pelvic masses. Obstet Gynecol. 1993;81(6):983–8. [PubMed: 8497367]
44.
Scoutt LM, McCarthy SM, Lange R. et al. MR evaluation of clinically suspected adnexal masses. J Comput Assist Tomogr. 1994;18(4):609–18. [PubMed: 8040448]
45.
Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gynecol Oncol. 2002;87(1):77–83. [PubMed: 12468346]
46.
Smikle CB, Lunt CC, Hankins GD. Clinical predictors in the evaluation of a pelvic mass. Mil Med. 1995;160(5):233–5. [PubMed: 7659211]
47.
Troiano RN, Quedens-Case C, Taylor KJ. Correlation of findings on transvaginal sonography with serum CA 125 levels. AJR Am J Roentgenol. 1997;168(6):1587–90. [PubMed: 9168732]
48.
Twickler DM, Forte TB, Santos-Ramos R. et al. The Ovarian Tumor Index predicts risk for malignancy. Cancer. 1999;86(11):2280–90. [PubMed: 10590369]
49.
van Nagell JR Jr, DePriest PD, Reedy MB. et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol. 2000;77(3):350–6. [PubMed: 10831341]
50.
Vasilev SA, Schlaerth JB, Campeau J. et al. Serum CA 125 levels in preoperative evaluation of pelvic masses. Obstet Gynecol. 1988;71(5):751–6. [PubMed: 3162763]
51.
Adonakis GL, Paraskevaidis E, Tsiga S. et al. A combined approach for the early detection of ovarian cancer in asymptomatic women. Eur J Obstet Gynecol Reprod Biol. 1996;65(2):221–5. [PubMed: 8730628]
52.
Andolf E, Jorgensen C, Astedt B. Ultrasound examination for detection of ovarian carcinoma in risk groups. Obstet Gynecol. 1990;75(1):106–9. [PubMed: 2404221]
53.
Balbi GC, Musone R, Menditto A. et al. Women with a pelvic mass: indicators of malignancy. Eur J Gynaecol Oncol. 2001;22(6):459–62. [PubMed: 11874083]
54.
Buckshee K, Temsu I, Bhatla N. et al. Pelvic examination, transvaginal ultrasound and transvaginal color Doppler sonography as predictors of ovarian cancer. Int J Gynaecol Obstet. 1998;61(1):51–7. [PubMed: 9622173]
55.
Dowd JR, Quinn MA, Rome R. et al. Women with a pelvic mass—when to perform an ultrasound. Aust N Z J Obstet Gynaecol. 1993;33(4):404–7. [PubMed: 8179554]
56.
Finkler NJ, Benacerraf B, Lavin PT. et al. Comparison of serum CA 125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol. 1988;72(4):659–64. [PubMed: 3047614]
57.
Grover SR, Quinn MA. Is there any value in bimanual pelvic examination as a screening test. Med J Aust. 1995;162(8):408–10. [PubMed: 7746172]
58.
Jacobs I, Stabile I, Bridges J. et al. Multimodal approach to screening for ovarian cancer. Lancet. 1988;1(8580):268–71. [PubMed: 2893084]
59.
Ong S, Duffy T, Murphy J. Transabdominal ultrasound and its correlation with clinical findings in gynaecology. Ir J Med Sci. 1996;165(4):268–70. [PubMed: 8990652]
60.
Padilla LA, Radosevich DM, Milad MP. Accuracy of the pelvic examination in detecting adnexal masses. Obstet Gynecol. 2000;96(4):593–8. [PubMed: 11004365]
61.
Padilla LA, Radosevich DM, Milad MP. Limitations of the pelvic examination for evaluation of the female pelvic organs. Int J Gynaecol Obstet. 2005;88(1):84–8. [PubMed: 15617719]
62.
Schutter EM, Kenemans P, Sohn C. et al. Diagnostic value of pelvic examination, ultrasound, and serum CA 125 in postmenopausal women with a pelvic mass. An international multicenter study. Cancer. 1994;74(4):1398–406. [PubMed: 8055463]
63.
Schutter EM, Sohn C, Kristen P. et al. Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72-4 in postmenopausal women with a pelvic mass: an international multicenter study. Gynecol Oncol. 1998;69(1):56–63. [PubMed: 9570999]
64.
Ueland F, DePriest P, DeSimone C, et al. The accuracy and examination under anesthesia and transvaginal sonography in evaluating ovarian size. Gynecol Oncol 2005 (in Press). [PubMed: 16084576]
65.
Alcazar JL, Castillo G. Comparison of 2-dimensional and 3-dimensional power-Doppler imaging in complex adnexal masses for the prediction of ovarian cancer. Am J Obstet Gynecol. 2005;192(3):807–12. [PubMed: 15746675]
66.
Alcazar JL, Errasti T, Zornoza A. et al. Transvaginal color Doppler ultrasonography and CA-125 in suspicious adnexal masses. Int J Gynaecol Obstet. 1999;66(3):255–61. [PubMed: 10580673]
67.
Alcazar JL, Galan MJ, Garcia-Manero M. et al. Three-dimensional sonographic morphologic assessment in complex adnexal masses: preliminary experience. J Ultrasound Med. 2003;22(3):249–54. [PubMed: 12636324]
68.
Alcazar JL, Lopez-Garcia G. Transvaginal color Doppler assessment of venous flow in adnexal masses. Ultrasound Obstet Gynecol. 2001;17(5):434–8. [PubMed: 11380970]
69.
Alcazar JL, Merce LT, Laparte C. et al. A new scoring system to differentiate benign from malignant adnexal masses. Am J Obstet Gynecol. 2003;188(3):685–92. [PubMed: 12634641]
70.
Anandakumar C, Chew S, Wong YC. et al. Role of transvaginal ultrasound color flow imaging and Doppler waveform analysis in differentiating between benign and malignant ovarian tumors. Ultrasound Obstet Gynecol. 1996;7:280–4. [PubMed: 8726882]
71.
Antonic J, Rakar S. Colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses. Anticancer Res. 1995;15:1527–32. [PubMed: 7654041]
72.
Asif N, Sattar A, Dawood MM. et al. Pre-operative evaluation of ovarian mass: risk of malignancy index. J Coll Physicians Surg Pak. 2004;14(3):128–31. [PubMed: 15228841]
73.
Benjapibal M, Sunsaneevitayakul P, Boriboonhirunsarn D. et al. Color Doppler ultrasonography for prediction of malignant ovarian tumors. J Med Assoc Thai. 2002;85(6):709–15. [PubMed: 12322845]
74.
Benjapibal M, Sunsaneevitayakul P, Phatihattakorn C. et al. Sonographic morphological pattern in the pre-operative prediction of ovarian masses. J Med Assoc Thai. 2003;86(4):332–7. [PubMed: 12757077]
75.
Berlanda N, Ferrari MM, Mezzopane R. et al. Impact of a multiparameter, ultrasound-based triage on surgical management of adnexal masses. Ultrasound Obstet Gynecol. 2002;20(2):181–5. [PubMed: 12153670]
76.
Bromley B, Goodman H, Benacerraf BR. Comparison between sonographic morphology and Doppler waveform for the diagnosis of ovarian malignancy. Obstet Gynecol. 1994;83(3):434–7. [PubMed: 8127538]
77.
Brown DL, Doubilet PM, Miller FH. et al. Benign and malignant ovarian masses: selection of the most discriminating gray-scale and Doppler sonographic features. Radiology. 1998;208(1):103–10. [PubMed: 9646799]
78.
Buist MR, Golding RP, Burger CW. et al. Comparative evaluation of diagnostic methods in ovarian carcinoma with emphasis on CT and MRI. Gynecol Oncol. 1994;52(2):191–8. [PubMed: 8314138]
79.
Buy JN, Ghossain MA, Hugol D. et al. Characterization of adnexal masses: combination of color Doppler and conventional sonography compared with spectral Doppler analysis alone and conventional sonography alone. AJR Am J Roentgenol. 1996;166(2):385–93. [PubMed: 8553953]
80.
Canis M, Pouly JL, Wattiez A. et al. Laparoscopic management of adnexal masses suspicious at ultrasound. Obstet Gynecol. 1997;89(5 Pt 1):679–83. [PubMed: 9166300]
81.
Carter JR, Lau M, Fowler JM. et al. Blood flow characteristics of ovarian tumors: implications for ovarian cancer screening. Am J Obstet Gynecol. 1995;172(3):901–7. [PubMed: 7892883]
82.
Carter PG, Iles RK, Neven P. et al. The measurement of urinary beta core fragment in conjunction with serum CA125 does not aid the differentiation of malignant from benign pelvic masses. Gynecol Oncol. 1993;51(3):368–71. [PubMed: 8112647]
83.
Caruso A, Caforio L, Testa AC. et al. Transvaginal color Doppler ultrasonography in the presurgical characterization of adnexal masses. Gynecol Oncol. 1996;63(2):184–91. [PubMed: 8910625]
84.
Chen DX, Schwartz PE, Li FQ. Saliva and serum CA 125 assays for detecting malignant ovarian tumors. Obstet Gynecol. 1990;75(4):701–4. [PubMed: 2179784]
85.
Chen DX, Schwartz PE, Li XG. et al. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol. 1988;72(1):23–7. [PubMed: 3164105]
86.
Chou CY, Chang CH, Yao BL. et al. Color Doppler ultrasonography and serum CA 125 in the differentiation of benign and malignant ovarian tumors. J Clin Ultrasound. 1994;22:491–6. [PubMed: 7814654]
87.
Davies AP, Jacobs I, Woolas R. et al. The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. Br J Obstet Gynaecol. 1993;100(10):927–31. [PubMed: 8217976]
88.
DePriest PD, Varner E, Powell J. The efficacy of a sonographic morphology index in identifying ovarian cancer: a multi-institutional investigation. Gynecol Oncol. 1994;55:174–8. [PubMed: 7959280]
89.
Einhorn N, Bast RC Jr, Knapp RC. et al. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol. 1986;67(3):414–6. [PubMed: 2418395]
90.
Ekerhovd E, Wienerroith H, Staudach A. et al. Preoperative assessment of unilocular adnexal cysts by transvaginal ultrasonography: a comparison between ultrasonographic morphologic imaging and histopathologic diagnosis. Am J Obstet Gynecol. 2001;184(2):48–54. [PubMed: 11174478]
91.
Fenchel S, Grab D, Nuessle K. et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology. 2002;223(3):780–8. [PubMed: 12034950]
92.
Ferdeghini M, Gadducci A, Prontera C. et al. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer. Tumour Biol. 1993;14(5):303–9. [PubMed: 8235309]
93.
Ferrazzi E, Zanetta G, Dordoni D. et al. Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study.[erratum appears in Ultrasound Obstet Gynecol 1998 Jan;11(1):v Note: Lissoni G[corrected to Lissoni AA]] Ultrasound Obstet Gynecol. 1997;10(3):192–7. [PubMed: 9339526]
94.
Fleischer AC, Rodgers WH, Kepple DM. et al. Color Doppler sonography of benign and malignant ovarian masses. Radiographics. 1992;12(5):879–85. [PubMed: 1529130]
95.
Franchi M, Beretta P, Ghezzi F. et al. Diagnosis of pelvic masses with transabdominal color Doppler, CA 125 and ultrasonography. Acta Obstet Gynecol Scand. 1995;74(9):734–9. [PubMed: 7572110]
96.
Gadducci A, Baicchi U, Marrai R. et al. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses. Gynecol Oncol. 1996;60(2):197–202. [PubMed: 8631538]
97.
Gadducci A, Capriello P, Bartolini T. et al. The association of ultrasonography and CA-125 test in the preoperative evaluation of ovarian carcinoma. Eur J Gynaecol Oncol. 1988;9(5):373–6. [PubMed: 3066622]
98.
Gadducci A, Ferdeghini M, Prontera C. et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol. 1992;44(2):147–54. [PubMed: 1312052]
99.
Gadducci A, Ferdeghini M, Rispoli G, et al. Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer. Scand J Clin Lab Invest Suppl 1991;207(19–24). [PubMed: 1780685]
100.
Grab D, Flock F, Stohr I. et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol. 2000;77(3):454–9. [PubMed: 10831359]
101.
Granberg S, Norstrom A, Wikland M. Tumors in the lower pelvis as imaged by vaginal sonography. Gynecol Oncol. 1990;37(2):224–9. [PubMed: 2188879]
102.
Granberg S, Norstrom A, Wikland M. Comparison ofendovaginal ultrasound and cytological evaluation of cystic ovarian tumors. J Ultrasound Med. 1991;10:9–14. [PubMed: 1997688]
103.
Guerriero S, Ajossa S, Risalvato A. et al. Diagnosis of adnexal malignancies by using color Doppler energy imaging as a secondary test in persistent masses. Ultrasound Obstet Gynecol. 1998;11(4):277–82. [PubMed: 9618853]
104.
Guerriero S, Ajossa S, Garau N. et al. Ultrasonography and color Doppler-based triage for adnexal masses to provide the most appropriate surgical approach. Am J Obstet Gynecol. 2005;192(2):401–6. [PubMed: 15695978]
105.
Guerriero S, Alcazar JL, Coccia ME. et al. Complex pelvic mass as a target of evaluation of vessel distribution by color Doppler sonography for the diagnosis of adnexal malignancies: results of a multicenter European study. J Ultrasound Med. 2002;21(10):1105–11. [PubMed: 12369665]
106.
Hata K, Hata T, Manabe A. et al. A critical evaluation of transvaginal Doppler studies, transvaginal sonography, magnetic resonance imaging, and CA 125 in detecting ovarian cancer. Obstet Gynecol. 1992;80(6):922–6. [PubMed: 1448260]
107.
Hata K, Hata T, Kitao M. Intratumoral peak systolic velocity as a new possible predictor for detection of adnexal malignancy. Am J Obstet Gynecol. 1995;172:1496–500. [PubMed: 7755061]
108.
Herrmann UJ Jr, Locher GW, Goldhirsch A. Sonographic patterns of ovarian tumors: prediction of malignancy. Obstet Gynecol. 1987;69(5):777–81. [PubMed: 3554058]
109.
Hillaby K, Aslam N, Salim R. et al. The value of detection of normal ovarian tissue (the ‘ovarian crescent sign’) in the differential diagnosis of adnexal masses. Ultrasound Obstet Gynecol. 2004;23(1):63–7. [PubMed: 14971002]
110.
Hogdall EV, Hogdall CK, Tingulstad S. et al. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. Int J Cancer. 2000;89(6):519–23. [PubMed: 11102897]
111.
Hricak H, Chen M, Coakley FV. et al. Complex adnexal masses: detection and characterization with MR imaging—multivariate analysis. Radiology. 2000;214(1):39–46. [PubMed: 10644099]
112.
Huber S, Medl M, Baumann L. et al. Value of ultrasound and magnetic resonance imaging in the preoperative evaluation of suspected ovarian masses. Anticancer Res. 2002;22(4):2501–7. [PubMed: 12174952]
113.
Hurteau JA, Woolas RP, Jacobs IJ. et al. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer. 1995;76(9):1615–20. [PubMed: 8635066]
114.
Inoue M, Fujita M, Nakazawa A. et al. Sialyl-Tn, sialyl-Lewis Xi, CA 19-9, CA 125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors. Obstet Gynecol. 1992;79(3):434–40. [PubMed: 1346716]
115.
Itakura T, Kikkawa F, Kajiyama H. et al. Doppler flow and arterial location in ovarian tumors. Int J Gynaecol Obstet. 2003;83(3):277–83. [PubMed: 14643038]
116.
Jacobs I, Oram D, Fairbanks J. et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990;97(10):922–9. [PubMed: 2223684]
117.
Jain KA. Prospective evaluation of adnexal masses with endovaginal gray-scale and duplex and color Doppler US: correlation with pathologic findings. Radiology. 1994;191(1):63–7. [PubMed: 8134599]
118.
Jain KA, Friedman DL, Pettinger TW. et al. Adnexal masses: comparison of specificity of endovaginal US and pelvic MR imaging. Radiology. 1993;186(3):697–704. [PubMed: 8430177]
119.
Juhasz B, Kurjak A, Lampe L. et al. Tissue characterization by transvaginal colour doppler for the evaluation of gynaecological tumours. Acta Med Hung. 1990;47:149–56. [PubMed: 1717935]
120.
Kawai M, Kikkawa F, Ishikawa H. Differential diagnosis of ovarian tumors by transvaginal color -pulse Doppler sonography. Gynecol Oncol. 1994;54:209–14. [PubMed: 8063248]
121.
Kawahara K, Yoshida Y, Kurokawa T. et al. Evaluation of positron emission tomography with tracer 18-fluorodeoxyglucose in addition to magnetic resonance imaging in the diagnosis of ovarian cancer in selected women after ultrasonography. J Comput Assist Tomogr. 2004;28(4):505–16. [PubMed: 15232382]
122.
Komatsu T, Konishi I, Mandai M. et al. Adnexal masses: transvaginal US and gadolinium-enhanced MR imaging assessment of intratumoral structure. Radiology. 1996;198(1):109–15. [PubMed: 8539360]
123.
Kurjak A, Kupesic S. Three dimensional ultrasound and power doppler in assessment of uterine and ovarian angiogenesis: a prospective study. Croat Med J. 1999;40(3):413–20. [PubMed: 10411971]
124.
Kurjak A, Kupesic S, Sparac V. et al. Three-dimensional ultrasonographic and power Doppler characterization of ovarian lesions. Ultrasound Obstet Gynecol. 2000;16(4):365–71. [PubMed: 11169314]
125.
Kurjak A, Predanic M. New scoring system for prediction of ovarian malignancy based on transvaginal color Doppler sonography. J Ultrasound Med. 1992;11(12):631–8. [PubMed: 1494195]
126.
Kurjak A, Schulman H, Sosic A. et al. Transvaginal ultrasound, color flow, and Doppler waveform of the postmenopausal adnexal mass. Obstet Gynecol. 1992;80(6):917–21. [PubMed: 1448259]
127.
Kurjak A, Shalan H, Kupesic S. et al. An attempt to screen asymptomatic women for ovarian and endometrial cancer with transvaginal color and pulsed Doppler sonography. J Ultrasound Med. 1994;13(4):295–301. [PubMed: 7932995]
128.
Kurjak A, Zalud I, Alfirevic Z. Evaluation of adnexal masses with transvaginal color ultrasound. J Ultrasound Med. 1991;10(6):295–7. [PubMed: 1895367]
129.
Kurtz AB, Tsimikas JV, Tempany CM. et al. Diagnosis and staging of ovarian cancer: comparative values of Doppler and conventional US, CT, and MR imaging correlated with surgery and histopathologic analysis—report of the Radiology Diagnostic Oncology Group. Radiology. 1999;212(1):19–27. [PubMed: 10405715]
130.
Leeners B, Schild RL, Funk A. et al. Colour Doppler sonography improves the pre-operative diagnosis of ovarian tumours made using conventional transvaginal sonography. Eur J Obstet Gynecol Reprod Biol. 1996;64(1):79–85. [PubMed: 8801156]
131.
Lerner JP, Timor-Tritsch IE, Federman A. et al. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. Am J Obstet Gynecol. 1994;170(1 Pt 1):81–5. [PubMed: 8296849]
132.
Lin P, Wu C, Lee C. et al. Color Doppler Ultrasound in the Assessment of Ovarian Neoplasms. J Med Ultrasound. 1993;1(4):172–6.
133.
Luxman D, Bergman A, Sagi J. et al. The postmenopausal adnexal mass: correlation between ultrasonic and pathologic findings. Obstet Gynecol. 1991;77(5):726–8. [PubMed: 2014086]
134.
Ma S, Shen K, Lang J. A risk of malignancy index in preoperative diagnosis of ovarian cancer. Chin Med J. 2003;116(3):396–9. [PubMed: 12781045]
135.
Maggino T, Gadducci A, D'Addario V. et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol. 1994;54(2):117–23. [PubMed: 8063233]
136.
Malkasian GD Jr, Knapp RC, Lavin PT. et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol. 1988;159(2):341–6. [PubMed: 2457318]
137.
Maly Z, Riss P, Deutinger J. Localization of blood vessels and qualitative assessment of blood flow in ovarian tumors. Obstet Gynecol. 1995;85(1):33–6. [PubMed: 7800320]
138.
Mancuso A, De Vivo A, Triolo O. et al. The role of transvaginal ultrasonography and serum CA 125 assay combined with age and hormonal state in the differential diagnosis of pelvic masses. Eur J Gynaecol Oncol. 2004;25(2):207–10. [PubMed: 15032283]
139.
Manjunath AP, Pratapkumar, Sujatha K. et al. Comparison of three risk of malignancy indices in evaluation of pelvic masses. Gynecol Oncol. 2001;81(2):225–9. [PubMed: 11330953]
140.
Marchetti M, Zambon A, Lamaina V. et al. Ultrasound as a possible screening method in ovarian cancer.[erratum appears in Eur J Gynaecol Oncol. 2002;23(3):172 Note: Marchioro S [corrected to Marchiori S]] Eur J Gynaecol Oncol. 2002;23(2):123–6. [PubMed: 12013107]
141.
Marret H, Sauget S, Giraudeau B. et al. Contrast-enhanced sonography helps in discrimination of benign from malignant adnexal masses. J Ultrasound Med. 2004;23(12):1629–39. quiz 1641–42. [PubMed: 15557306]
142.
Matthes AC, Moreira de Andrade JM, Bighetti S. Selection of criteria for the treatment of ovarian cysts on the bases of ultrasound and cytology. Gynecol Obstet Invest. 1996;42:244–8. [PubMed: 8979096]
143.
McIntosh MW, Drescher C, Karlan B. et al. Combining CA125 and SMR serum markers for diagnosis and early detection of ovarian cancer. Gynecol Oncol. 2004;95:9–15. [PMC free article: PMC2734270] [PubMed: 15385104]
144.
Medl M, Kulenkampff KJ, Stiskal M. et al. Magnetic resonance imaging in the preoperative evaluation of suspected ovarian masses. Anticancer Res. 1995;15(3):1123–5. [PubMed: 7645935]
145.
Menon U, Talaat A, Rosenthal AN. et al. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG. 2000;107(2):165–9. [PubMed: 10688498]
146.
Merce LT, Caballero RA, Barco MJ. et al. B-mode, utero-ovarian and intratumoural transvaginal colour Doppler ultrasonography for differential diagnosis of ovarian tumours. Eur J Obstet Gynecol Reprod Biol. 1998;76(1):97–107. [PubMed: 9481556]
147.
Morgante G, la Marca A, Ditto A. et al. Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses. Br J Obstet Gynaecol. 1999;106(6):524–7. [PubMed: 10426607]
148.
O'Connell GJ, Ryan E, Murphy KJ. et al. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses. Obstet Gynecol. 1987;70(6):930–2. [PubMed: 3479735]
149.
Onsrud M, Shabana A, Austgulen R. Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer. Tumour Biol. 1996;17(2):90–6. [PubMed: 8658018]
150.
Padungsutt P, Thirapagawong C, Senapad S. et al. Accuracy of tissue polypeptide specific antigen (TPS) in the diagnosis of ovarian malignancy. Anticancer Res. 2000;20(2B):1291–5. [PubMed: 10810437]
151.
Patsner B, Mann WJ. The value of preoperative serum CA 125 levels in patients with a pelvic mass. Am J Obstet Gynecol. 1988;159(4):873–6. [PubMed: 3052078]
152.
Prompeler HJ, Madjar H, Sauerbrei W. Classification of adnexal tumors by transvaginal color Doppler. Gynecol Oncol. 1996;61(3):354–63. [PubMed: 8641615]
153.
Pyrgiotis E, Salamalekis E, Loghis C. et al. CA 125 in preoperative evaluation of pelvic masses. Eur J Gynaecol Oncol. 1993;14(4):279–82. [PubMed: 8344320]
154.
Rehn M, Lohmann K, Rempen A. Transvaginal ultrasonography of pelvic masses: evaluation of B-mode technique and Doppler ultrasonography. Am J Obstet Gynecol. 1996;175(1):97–104. [PubMed: 8694082]
155.
Reles A, Wein U, Lichtenegger W. Transvaginal color Doppler sonography and conventional sonography in the preoperative assessment of adnexal masses. J Clin Ultrasound. 1997;25(5):217–25. [PubMed: 9314102]
156.
Reuter M, Steffens J., Schuppler U. Critical evaluation of the specificity of MRI and TVUs for differentiation of malignant from benign adnexal lesions. Eur Radiol 1998;8(39–44). [PubMed: 9442126]
157.
Roman LD, Muderspach LI, Burnett AF. et al. Carcinoembryonic antigen in women with isolated pelvic masses. Clinical utility? J Reprod Med. 1998;43(5):403–7. [PubMed: 9610461]
158.
Salem S, White LM, Lai J. Doppler sonography of adnexal masses: the predictive value of the pulsatility index in benign and malignant disease. AJR Am J Roentgenol. 1994;163(5):1147–50. [PubMed: 7976891]
159.
Sassone AM, Timor-Tritsch IE, Artner A. et al. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol. 1991;78(1):70–6. [PubMed: 2047071]
160.
Sawicki W, Spiewankiewicz B, Cendrowski K. et al. Preoperative discrimination between malignant and benign adnexal masses with transvaginal ultrasonography and colour blood flow imaging. Eur J Gynaecol Oncol. 2001;22(2):137–42. [PubMed: 11446479]
161.
Schelling M, Braun M, Kuhn W. et al. Combined transvaginal B-mode and color Doppler sonography for differential diagnosis of ovarian tumors: results of a multivariate logistic regression analysis. Gynecol Oncol. 2000;77(1):78–86. [PubMed: 10739694]
162.
Schutter EM, Davelaar EM, van Kamp GJ. et al. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass. Am J Obstet Gynecol. 2002;187(2):385–92. [PubMed: 12193930]
163.
Sengoku K, Satoh T, Saitoh S. et al. Evaluation of transvaginal color Doppler sonography, transvaginal sonography and CA 125 for prediction of ovarian malignancy. Int J Gynaecol Obstet. 1994;46(1):39–43. [PubMed: 7805982]
164.
Shabana A, Onsrud M. Tissue polypeptide-specific antigen and CA 125 as serum tumor markers in ovarian carcinoma. Tumour Biol. 1994;15(6):361–7. [PubMed: 7997808]
165.
Siegel BA, Dehdashti F, Mutch DG. et al. Evaluation of 111In-DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med. 2003;44(5):700–7. [PubMed: 12732670]
166.
Sohaib SA, Mills TD, Sahdev A. et al. The role of magnetic resonance imaging and ultrasound in patients with adnexal masses. Clin Radiol. 2005;60(3):340–8. [PubMed: 15710137]
167.
Soper JT, Hunter VJ, Daly L. et al. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol. 1990;75(2):249–54. [PubMed: 2300353]
168.
Stein SM, Laifer-Narin S, Johnson MB. et al. Differentiation of benign and malignant adnexal masses: relative value of gray-scale, color Doppler, and spectral Doppler sonography. AJR Am J Roentgenol. 1995;164(2):381–6. [PubMed: 7839975]
169.
Strigini FA, Gadducci A, Del Bravo B. et al. Differential diagnosis of adnexal masses with transvaginal sonography, color flow imaging, and serum CA 125 assay in pre- and postmenopausal women. Gynecol Oncol. 1996;61(1):68–72. [PubMed: 8626120]
170.
Szpurek D, Moszyniki R, Sajdak S. Clinical value of the ultrasound Doppler index in determination of ovarian tumor malignancy. Eur J Gynaecol Oncol. 2004;25(4):442–4. [PubMed: 15285299]
171.
Tailor A, Bourne TH, Campbell S. et al. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study. Ultrasound Obstet Gynecol. 2003;21(4):378–85. [PubMed: 12704748]
172.
Takac I. Analysis of blood flow in adnexal tumors by using color Doppler imaging and pulsed spectral analysis. Ultrasound Med Biol. 1998;24(8):1137–42. [PubMed: 9833582]
173.
Tanir HM, Ozalp S, Yalcin OT. et al. Preoperative serum vascular endothelial growth factor (VEGF) in ovarian masses. Eur J Gynaecol Oncol. 2003;24(34):271–4. [PubMed: 12807238]
174.
Tay SK, Chua EK. Correlation of serum, urinary and salivary CA 125 levels in patients with adnexal masses. Ann Acad Med Singapore. 1994;23(3):311–4. [PubMed: 7944239]
175.
Tekay A, Jouppila P. Validity of pulsatility and resistance indices in classification of adnexal tumors with transvaginal color doppler ultrasound. Ultrasound Obstet Gynecol. 1992;2:338–44. [PubMed: 12796933]
176.
Tepper R, Lerner-Geva L, Altaras MM. et al. Transvaginal color flow imaging in the diagnosis of ovarian tumors. J Ultrasound Med. 1995;14(10):731–4. [PubMed: 8544238]
177.
Tian J, Zhang J, Jiao L. et al. A prospective study of Tc-99m MIBI in the differential diagnosis of pelvic masses in female patients. Clin Nucl Med. 2000;25(8):614–8. [PubMed: 10944017]
178.
Timmerman D, Verrelst H, Bourne TH. et al. Artificial neural network models for the preoperative discrimination between malignant and benign adnexal masses. Ultrasound Obstet Gynecol. 1999;13(1):17–25. [PubMed: 10201082]
179.
Timor-Tritsch LE, Lerner J, Monteagudo A. et al. Transvaginal ultrasonographic characterization of ovarian masses by means of color flow-directed Doppler measurements and a morphologic scoring system. Am J Obstet Gynecol. 1993;168:909–13. [PubMed: 8456900]
180.
Tingulstad S, Hagen B, Skjeldestad FE. et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol. 1996;103(8):826–31. [PubMed: 8760716]
181.
Torres JC, Derchain SF, Faundes A. et al. Risk-of-malignancy index in preoperative evaluation of clinically restricted ovarian cancer. Rev Paul Med. 2002;120(3):72–6. [PubMed: 12163896]
182.
Valentin L. Gray scale sonography, subjective evaluation of the color Doppler image and measurement of blood flow velocity for distinguishing benign and malignant tumors of suspected adnexal origin. Eur J Obstet Gynecol Reprod Biol. 1997;72(1):63–72. [PubMed: 9076424]
183.
Valentin L. Pattern recognition of pelvic masses by gray-scale ultrasound imaging: the contribution of Doppler ultrasound. Ultrasound Obstet Gynecol. 1999;14(5):338–47. [PubMed: 10623994]
184.
Valentin L. Comparison of Lerner score, Doppler ultrasound examination, and their combination for discrimination between benign and malignant adnexal masses. Ultrasound Obstet Gynecol. 2000;15(2):143–7. [PubMed: 10775998]
185.
Valentin L, Hagen B, Tingulstad S. et al. Comparison of ‘pattern recognition’ and logistic regression models for discrimination between benign and malignant pelvic masses: a prospective cross validation. Ultrasound Obstet Gynecol. 2001;18(4):357–65. [PubMed: 11778996]
186.
Vuento MH, Pirhonen JP, Makinen JI. et al. Evaluation of ovarian findings in asymptomatic postmenopausal women with color Doppler ultrasound. Cancer. 1995;76(7):1214–8. [PubMed: 8630900]
187.
Wakahara F, Kikkawa F, Nawa A. et al. Diagnostic efficacy of tumor markers, sonography, and intraoperative frozen section for ovarian tumors. Gynecol Obstet Invest. 2001;52(3):147–52. [PubMed: 11598354]
188.
Weiner Z, Thaler I, Beck D. et al. Differentiating malignant from benign ovarian tumors with transvaginal color flow imaging. Obstet Gynecol. 1992;79(2):159–62. [PubMed: 1731278]
189.
Woolas RP, Conaway MR, Xu F. et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol. 1995;59(1):111–6. [PubMed: 7557595]
190.
Wu CC, Lee CN, Chen T. et al. Factors contributing to the accuracy in diagnosing ovarian malignancy by color Doppler ultrasound. Obstet Gynecol. 1994;84:605–8. [PubMed: 8090400]
191.
Yamashita Y, Hatanaka Y, Torashima M. et al. Characterization of sonographically indeterminate ovarian tumors with MR imaging. A logistic regression analysis. Acta Radiol. 1997;38(4 Pt 1):572–7. [PubMed: 9240680]
192.
Yamashita Y, Torashima M, Hatanaka Y. et al. Adnexal masses: accuracy of characterization with transvaginal US and precontrast and postcontrast MR imaging. Radiology. 1995;194(2):557–65. [PubMed: 7824738]
193.
Zanetta G, Vergani P, Lissoni A. Color Doppler ultrasound in the preoperative assessment of adnexal masses. Acta Obstet Gynecol Scand. 1994;73:637–41. [PubMed: 7941989]
194.
Zhang Z, Barnhill SD, Zhang H. et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol. 1999;73(1):56–61. [PubMed: 10094881]
195.
Zimmer Y, Tepper R, Akselrod S. An automatic approach for morphological analysis and malignancy evaluation of ovarian masses using B-scans. Ultrasound Med Biol. 2003;29(11):1561–70. [PubMed: 14654152]
196.
Timmerman D, Schwarzler P, Collins WP. et al. Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience. Ultrasound Obstet Gynecol. 1999;13(1):11–6. [PubMed: 10201081]
197.
Kinkel K, Hricak H, Lu Y. et al. US characterization of ovarian masses: a meta-analysis. Radiology. 2000;217(3):803–11. [PubMed: 11110947]
198.
Larsen T, Torp-Pedersen ST, Ottesen M. et al. Abdominal ultrasound combined with histological and cytological fine needle biopsy of suspected ovarian tumors. Eur J Obstet Gynecol Reprod Biol. 1993;50(3):203–9. [PubMed: 8262297]
199.
Alcazar JL, Ruiz-Perez ML, Errasti T. Transvaginal color Doppler sonography in adnexal masses: which parameter performs best? Ultrasound Obstet Gynecol. 1996;8(2):114–9. [PubMed: 8883314]
200.
Kurjak A, Shalan H, Kupesic S. et al. Transvaginal color Doppler sonography in the assessment of pelvic tumor vascularity. Ultrasound Obstet Gynecol. 1993;3(2):137–54. [PubMed: 12797309]
201.
Valentin L. Prospective cross-validation of Doppler ultrasound examination and gray-scale ultrasound imaging for discrimination of benign and malignant pelvic masses. Ultrasound Obstet Gynecol. 1999;14(4):273–83. [PubMed: 10586480]
202.
Andersen ES, Knudsen A, Rix P. et al. Risk of malignancy index in the preoperative evaluation of patients with adnexal masses. Gynecol Oncol. 2003;90(1):109–12. [PubMed: 12821350]
203.
Aslam N, Banerjee S, Carr JV. et al. Prospective evaluation of logistic regression models for the diagnosis of ovarian cancer. Obstet Gynecol. 2000;96(1):75–80. [PubMed: 10862846]
204.
Aslam N, Tailor A, Lawton F. et al. Prospective evaluation of three different models for the pre-operative diagnosis of ovarian cancer. BJOG. 2000;107(11):1347–53. [PubMed: 11117760]
205.
Biagiotti R, Desii C, Vanzi E. et al. Predicting ovarian malignancy: application of artificial neural networks to transvaginal and color Doppler flow US. Radiology. 1999;210(2):399–403. [PubMed: 10207421]
206.
Lu C, Van Gestel T, Suykens JA. et al. Preoperative prediction of malignancy of ovarian tumors using least squares support vector machines. Artif Intell Med. 2003;28(3):281–306. [PubMed: 12927337]
207.
Mol BW, Boll D, De Kanter M. et al. Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models. Gynecol Oncol. 2001;80(2):162–7. [PubMed: 11161854]
208.
Obeidat BR, Amarin ZO, Latimer JA. et al. Risk of malignancy index in the preoperative evaluation of pelvic masses. Int J Gynaecol Obstet. 2004;85(3):255–8. [PubMed: 15145261]
209.
Tailor A, Jurkovic D, Bourne TH. et al. Sonographic prediction of malignancy in adnexal masses using an artificial neural network. Br J Obstet Gynaecol. 1999;106(1):21–30. [PubMed: 10426255]
210.
Timmerman D, Bourne TH, Tailor A. et al. A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model. Am J Obstet Gynecol. 1999;181(1):57–65. [PubMed: 10411796]
211.
Tingulstad S, Hagen B, Skjeldestad FE. et al. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol. 1999;93(3):448–52. [PubMed: 10074998]
212.
Jacobs IJ, Rivera H, Oram DH. et al. Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. Br J Obstet Gynaecol. 1993;100(12):1120–4. [PubMed: 8297846]
213.
Alcazar JL, Jurado M. Using a logistic model to predict malignancy of adnexal masses based on menopausal status, ultrasound morphology, and color Doppler findings. Gynecol Oncol. 1998;69(2):146–50. [PubMed: 9600822]
214.
Castillo G, Alcazar JL, Jurado M. Natural history of sonographically detected simple unilocular adnexal cysts in asymptomatic postmenopausal women. Gynecol Oncol. 2004;92(3):965–9. [PubMed: 14984967]
215.
Goldstein SR, Subramanyam B, Snyder JR. et al. The postmenopausal cystic adnexal mass: the potential role of ultrasound in conservative management. Obstet Gynecol. 1989;73(1):8–10. [PubMed: 2642328]
216.
Levine D, Gosink BB, Wolf SI. et al. Simple adnexal cysts: the natural history in postmenopausal women.[see comment] Radiology. 1992;184(3):653–9. [PubMed: 1509047]
217.
Schincaglia P, Brondelli L, Cicognani A. et al. A feasibility study of ovarian cancer screening: does fine-needle aspiration improve ultrasound specificity? Tumori. 1994;80(3):181–7. [PubMed: 8053074]
218.
Valentin L, Akrawi D. The natural history of adnexal cysts incidentally detected at transvaginal ultrasound examination in postmenopausal women. Ultrasound Obstet Gynecol. 2002;20(2):174–80. [PubMed: 12153669]
219.
Canis M, Mage G, Pouly JL. et al. Laparoscopic diagnosis of adnexal cystic masses: a 12-year experience with long-term follow-up. Obstet Gynecol. 1994;83(5 Pt 1):707–12. [PubMed: 8164928]
220.
Canis M, Mashiach R, Wattiez A. et al. Frozen section in laparoscopic management of macroscopically suspicious ovarian masses. J Am Assoc Gynecol Laparosc. 2004;11(3):365–9. [PubMed: 15559350]
221.
Carley ME, Klingele CJ, Gebhart JB. et al. Laparoscopy versus laparotomy in the management of benign unilateral adnexal masses. J Am Assoc Gynecol Laparosc. 2002;9(3):321–6. [PubMed: 12101329]
222.
Chapron C, Dubuisson JB, Capella-Allouc S. Salpingo-oophorectomy for adnexal masses. Place and results for operative laparoscopy. Eur J Obstet Gynecol Reprod Biol. 1997;73(1):43–8. [PubMed: 9175688]
223.
Chi DS, Abu-Rustum NR, Sonoda Y. et al. Ten-year experience with laparoscopy on a gynecologic oncology service: analysis of risk factors for complications and conversion to laparotomy. Am J Obstet Gynecol. 2004;191(4):1138–45. [PubMed: 15507933]
224.
Deckardt R, Saks M, Graeff H. Comparison of minimally invasive surgery and laparotomy in the treatment of adnexal masses. J Am Assoc Gynecol Laparosc. 1994;1(4 Pt 1):333–8. [PubMed: 9138874]
225.
Fanfani F, Fagotti A, Ercoli A. et al. A prospective randomized study of laparoscopy and minilaparotomy in the management of benign adnexal masses. Hum Reprod. 2004;19(10):2367–71. [PubMed: 15242993]
226.
Havrilesky LJ, Peterson BL, Dryden DK. et al. Predictors of clinical outcomes in the laparoscopic management of adnexal masses. Obstet Gynecol. 2003;102(2):243–51. [PubMed: 12907095]
227.
Hidlebaugh DA, Vulgaropulos S, Orr RK. Treating adnexal masses. Operative laparoscopy vs. laparotomy. J Reprod Med. 1997;42(9):551–8. [PubMed: 9336750]
228.
Lok IH, Sahota DS, Rogers MS. et al. Complications of laparoscopic surgery for benign ovarian cysts. J Am Assoc Gynecol Laparosc. 2000;7(4):529–34. [PubMed: 11044507]
229.
Mann WJ, Reich H. Laparoscopic adnexectomy in postmenopausal women. J Reprod Med. 1992;37(3):254–6. [PubMed: 1532991]
230.
Marana R, Muzii L, Catalano GF. et al. Laparoscopic excision of adnexal masses. J Am Assoc Gynecol Laparosc. 2004;11(2):162–6. [PubMed: 15200767]
231.
Parker J, Proietto AM. Surgical treatment of adnexal cysts by laparotomy. Int J Gynaecol Obstet. 1997;59(3):257–8. [PubMed: 9486518]
232.
Sadik S, Onoglu AS, Gokdeniz R. et al. Laparoscopic management of selected adnexal masses. J Am Assoc Gynecol Laparosc. 1999;6(3):313–6. [PubMed: 10459033]
233.
Serur E, Emeney PL, Byrne DW. Laparoscopic management of adnexal masses. J Soc Laparoendosc Surg. 2001;5(2):143–51. [PMC free article: PMC3015439] [PubMed: 11394427]
234.
Shalev E, Eliyahu S, Peleg D. et al. Laparoscopic management of adnexal cystic masses in postmenopausal women. Obstet Gynecol. 1994;83(4):594–6. [PubMed: 8134071]
235.
Somigliana E, Ragni G, Benedetti F. et al. Does laparoscopic excision of endometriotic ovarian cysts significantly affect ovarian reserve? Insights from IVF cycles. Hum Reprod. 2003;18(11):2450–3. [PubMed: 14585900]
236.
Tangjitgamol S, Jesadapatrakul S, Manusirivithaya S. et al. Accuracy of frozen section in diagnosis of ovarian mass. Int J Gynecol Cancer. 2004;14(2):212–9. [PubMed: 15086718]
237.
Tarik A, Fehmi C. Complications of gynaecological laparoscopy—a retrospective analysis of 3572 cases from a single institute. J Obstet Gynaecol. 2004;24(7):813–6. [PubMed: 15763797]
238.
van Herendael B, Beretta P, Slangen T. et al. Management of adnexal masses by operative laparoscopy. J Am Assoc Gynecol Laparosc. 1995;2(3):273–7. [PubMed: 9050570]
239.
Yuen PM, Yu KM, Yip SK. et al. A randomized prospective study of laparoscopy and laparotomy in the management of benign ovarian masses. Am J Obstet Gynecol. 1997;177(1):109–14. [PubMed: 9240592]
240.
Myers ER, McCrory DC, Nanda K. et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol. 2000;151(12):1158–71. [PubMed: 10905528]
241.
Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004;103(4):619–31. [PubMed: 15051550]
242.
Schapira MM, Matchar DB, Young MJ. The effectiveness of ovarian cancer screening. A decision analysis model. Ann Intern Med. 1993;118(11):838–43. [PubMed: 8480957]
243.
Urban N, Drescher C, Etzioni R. et al. Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening. Control Clin Trials. 1997;18(3):251–70. [PubMed: 9204225]
244.
Skates SJ, Singer DE. Quantifying the potential benefit of CA 125 screening for ovarian cancer. J Clin Epidemiol. 1991;44(45):365–80. [PubMed: 2010780]
245.
Tengs TO, Winer EP, Paddock S. et al. Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. Med Decis Making. 1998;18(4):365–75. [PubMed: 10372578]
246.
Bast RC Jr, Urban N, Shridhar V. et al. Early detection of ovarian cancer: promise and reality. Cancer Treat Res. 2002;107:61–97. [PubMed: 11775462]
247.
Im S, Gordon A, Buttin B. et al. Validation of referral guidelines for women with pelvic masses. Obstet Gyencol. 2005;205(1):35–41. [PubMed: 15625139]

Views

  • PubReader
  • Print View
  • Cite this Page

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...